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To the Editor
The long-term survival rates of human islet allografts
are unsatisfactorily low (1). Despite improved immu-
nosuppressive protocols, only approximately 10% of the
recipients are still normoglycemic and insulin indepen-
dent at 5 years after transplantation. For a long time,
the role of cytomegalovirus (CMV) in islet graft failure
was neglected, as its effect could not be reliably
determined because of the overshadowing effects of
other deleterious factors, such as recurring autoimmu-
nity, alloimmunity, or a combination of these (1).
However, recently, CMV has been recognized, both in
experimental animals and in humans, as a possible risk
factor contributing to islet graft failure (2).
In our efforts to identify the mechanisms by which
CMV contributes to failure, we demonstrated that CMV
could directly infect human and rat beta cells in vitro
(3, 4). In vivo, in rat islet allografts in rats, we showed
that rat CMV (RCMV) accelerates failure of the grafts
(5). Also, the routinely applied antiviral treatment with
ganciclovir has been shown not to be effective in
blocking the negative effects of RCMV (5). Antiviral
treatment blocks replication of the virus, but cannot
prevent adverse effects on the cells such as elevated
immunogenicity (5).
We found evidence that the accelerated allograft
failure could be explained by CMV-induced enhance-
ment of allogeneic CD8+ and NK cells responses (5). A
question that could not be addressed in our previous
studies was whether RCMV also has direct effects on
the grafts in vivo (5). Therefore, we undertook this
study, in which we determined the direct effect of
RCMV on the functional survival of islets by performing
infections in isografts, thus, in the absence of
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confounding allogeneic immune responses. This study
was done with low doses of RCMV, to be able to
determine whether RCMV might influence graft func-
tion even in the absence of clinical viremia and
characteristic clinical symptoms.
To this end, diabetic Albino Oxford rats, induced
with streptozotocin (via the tail vein with 75 mg/kg of
Zonasar; Upjohn Co., Kalamazoo, Michigan, USA),
were transplanted with a syngeneic islet graft. The
baseline glucose levels before streptozotocin injection
were always between 5 and 5.5 mM glucose and
before islet transplantation between 19 and 30 mM
glucose. No statistically significant differences were
found in these values between the different groups.
The endocrine graft volume was 5 lL, which induces
normoglycemia in 100% of the non-CMV infected
recipients (5). Islets were transplanted under the
kidney capsule. Transplantation was considered suc-
cessful when non-fasting blood glucose concentra-
tions reached levels <10 mmol/L. At the time of
sacrifice we took biopsies from the na€ıve pancreas to
exclude pancreas regeneration, as previously
described (6). To mimic a primary RCMV infection
in a negative recipient, the islet graft recipients
received an RCMV infection (n = 7) (Maastricht
strain) of 2 9 105 plaque-forming units at day 1 after
implantation. Control animals (n = 6) received the
homogenate without the virus; this is called a mock
infection. Three weeks after transplantation, all suc-
cessful graft recipients received a permanent silicone
catheter in the right jugular vein, for blood sampling
and infusion of glucose in unanesthetized, undis-
turbed animals. RCMV-specific (nested) polymerase
chain reaction (PCR) analysis was performed as
described previously (5). Results are presented as
the mean  standard error of mean. Statistical signif-
icance was calculated using the Mann–Whitney U-test.
P-values <0.05 were considered to be statistically
significant.
In RCMV-infected animals it took 10.8  3.1 days
before normoglycemia was established after islet
transplantation. In the mock-treated controls this was
faster, i.e., 7.8  1.7 days. This difference did not
reach statistical significance. Normoglycemia was
maintained in all control recipients for the study period
of 90 days. In the RCMV-infected animals, this was 83%
instead of 100%, illustrating that in isografts an effect
of RCMV on the success rate of the grafts can be
measured.
The metabolic capacity of successful grafts was
studied at day 28 after implantation by performing a
meal test. At this time point, 4 animals were sacrificed.
In the salivary glands we found no expression of RCMV
by PCR (5), confirming that the infection is subclinical
and does not lead to viremia. RCMV-specific R44
protein was demonstrated in the grafts by immunohis-
tochemistry, as described (5). We inspected the grafts
for RCMV R44 protein, but, as also shown in our
previous study, infected cells were rare or absent (5).
Only a small portion of the cells are infected, but are
responsible for dysfunction, as we showed for human
and rat islets (3, 4).
As demonstrated in Figure 1, RCMV-infected recip-
ients were less glucose tolerant than the control
animals, as illustrated by the higher glucose levels
and the lower insulin responses during the meal test
(areas under the curve calculations showed that P was
always <0.05). To determine whether this was a result
of a decreased beta cell mass or should be attributed to
a disturbed potentiation of the response, we also
performed an intravenous glucose tolerance test by
administering a glucose bolus infusion of 200 mg of
glucose (n = 6). This intravenous glucose tolerance
test did not demonstrate any differences in glucose or
insulin levels, illustrating that it was not the beta cell
mass but rather a disturbed potentiation of the
response that should be held responsible for the
reduced responses during the meal test (7, 8). In a
previous study, we showed that only a few cells in the
graft are infected but responsible for enhancement of
the immunogenicity of the graft as a whole (3, 4). So we
show that not only enhancement of allogenic CD8+ and
NK cell responses is involved in islet grafts failure (5)
but also more direct effects on the grafts, as allograft
responses were excluded in the present experimental
set up. Possibly, RCMV-specific T and NK cells are
involved. These cells are also likely a portion of the NK
cells we observed to be enhanced in our previous
study (5).
As we found only a few beta cells to be infected by
RCMV in the present and previous studies (3, 4), we
believe we can conclude that the increased immunoge-
nicity and cytokine expression in the beta cells (3, 4),
after RCMV infection, should be held responsible for the
disturbed engraftment and reduced responses during
the meal test.
Up to now, many clinicians neglect CMV as a threat
for islet graft function when viremia is absent. Viremia
and CMV disease is assumed to be a mandatory
hallmark to consider CMV as a factor influencing graft
function (9). We were not able to detect viremia in the
CMV group. Furthermore, the group did not develop
clinical CMV. Despite these facts, we still found many
undesired effects of CMV, such as a disturbed glucose
tolerance as shown in this report, and accelerated graft
failure with allografts (5). Our argument is supported
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by Hayashi and Fujisaki (10) in mice, who demon-
strated impaired insulin secretion by native pancreatic
beta cells after CMV infection of fully immunocompe-
tent mice. Our data also corroborated the findings of
Eckhard et al. (11), who also found evidence that, in
the absence of CMV disease, human islet allograft
function may be impaired. Only studying effects in
patients with viremia may therefore lead to an under-
estimation of the effects of CMV on impaired graft
function.
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considered to be statistically significant.
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